COMMENT

The FNIH Biomarkers Consortium embraces the BEST

The Biomarkers Consortium aims to facilitate drug development with biomarkers across a range of diseases. Here, we briefly highlight its accomplishments so far and its recent expansion in scope to include related tools along the lines of the Biomarkers, EndpointS and other Tools (BEST) resource, such as patient-reported outcomes and clinical outcome assessments.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Nature Reviews Drug Discovery 18, 567-568 (2019)

Acknowledgements

The authors acknowledge the contribution of J. Altshuler and S. Staats from Altshuler and Staats for their work on the strategic analysis, as well as the support and feedback from the members of the Biomarkers Consortium executive committee, particularly P. Herrling, chair of the executive committee and FNIH board member.

References

  1. 1.

    Powers, J. H. et al. Patient-reported outcome assessments as endpoints in studies in infectious diseases. Clin. Infect. Dis. 63, S52–S56 (2016).

  2. 2.

    Carey, L. A. & Winer, E. P. I-SPY 2–Toward more rapid progress in breast cancer treatment. N. Engl. J. Med. 375, 83–84 (2016).

  3. 3.

    Leptak, C. et al. What evidence do we need for biomarker qualification? Sci. Transl Med. 9, eaal4599 (2017)

Download references

Competing Interests

J.A.W. is an employee of Takeda Pharmaceuticals. J.P.M., C.A., L.S.B., G.E., C.L. and A.M. declare no conflicts.

Nature Briefing

An essential round-up of science news, opinion and analysis, delivered to your inbox every weekday.

Subjects

Sign up to Nature Briefing

An essential round-up of science news, opinion and analysis, delivered to your inbox every weekday.

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing